OssulinTM, a Novel Oral Insulin Product, Shows Promising Bioavailability for Advancing Diabetes Therapy
|
| Posted
:
Mon, 09 Nov 2009 10:00:37 GMT |
| Author
:
CM&D Pharma Limited
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
LONDON - (Business Wire) New data from Puredel Limited, presented at the 9th Annual Diabetes Technology Meeting in San Francisco, CA, suggests that higher blood levels of insulin were achieved by Ossulin™ than had been previously demonstrated by other oral products. In a series of experiments covering a range of doses and models, Ossulin™ consistently delivered around 20% of the insulin dose into the bloodstream. The authors concluded that: | "Ossulin provides an efficient way to deliver insulin to the body via oral administration, resulting in blood levels higher than those previously observed with other oral insulin products." | Lead author and Chief Scientific Officer for Puredel, Dr. Marco Prosdocimi added: | "Oral insulin could represent a major advance in diabetes therapy through its simplicity of use, and because it mimics the natural physiological route of the hormone. The incorporation of insulin into the proprietary delivery agent NatsomTM gives rise to a product which is not destroyed by the gastric environment." | About Puredel Limited Puredel is focusing its research on the development of Ossulin™, which has shown promising results in preliminary studies. Puredel will also explore other target molecules which are currently injected, and whose oral administration would greatly improve patient convenience and compliance. Natreon’s R&D staff and facilities in the United States and India are working closely with Puredel to help facilitate the next stage of scientific validation prior to commercial development. Puredel will coordinate the product development of Ossulin™ up to proof of clinical efficacy, drawing on its extensive network of scientific experts in Europe and North America.
CM&D Pharma Limited
Stephen Appelbee, CEO, +44 20 7259 8488
appelbee@cmdpharmaltd.com
www.cmdpharmaltd.com
|
Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
Enigma Diagnostics Expands Its US and European Executive Management Teams
OXFORD, England and SAN DIEGO, Nov. 24 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today four senior appointments for its US and European offices.
Dr. Jorge Garces will lead the US team as Presiden...
Leahy Hits U.S. Refusal to Join Landmine Treaty
WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- Sen. Patrick Leahy (D-Vt.) is sharply critical of the Obama Administration's decision, announced Tuesday by the State Department, to decline to join the international treaty to ban anti-personnel landmines, a weapon that kills or maims thou...
OKI Electric Cable Launches VEYOR-CABLE™ Smooth-Sliding Parallel Robot Cables
KANAGAWA, Japan -
OKI
Electric Cable (TOKYO:5815) today
Taipei Starts Countdown to 2010 Flora Expo
TAIPEI,Taiwan -
Taipei Mayor Hau Lung-bin announced on Nov. 6 the countdown of exactly
365 days to the opening of the 2010 Taipei International Gardening and
Horticulture Exposition and urged other cities and counties of Taiwan to
join Taipei City in putting Taiwan in the spotlight on the wo
Overstock.com Chairman and CEO Corrects Misstatements in Grant Thornton Letter to SEC
SALT LAKE CITY, Nov. 24 -- Overstock.com, Inc. (Nasdaq: OSTK) yesterday filed a Form 8-K/A which included a letter from the company's former auditor to the SEC. Below is a letter from Patrick Byrne, the company's Chairman and CEO, commenting on Grant Thornton...
EACOM Timber Corporation: Warrant Holders Exercise $2.4 Million of Warrants Early
VANCOUVER, BRITISH COLUMBIA -- 11/24/09 --
EACOM Timber Corporation (NEX: ETR.H) today announced it has received proceeds of $2,406,250 related to the early exercise of 9,625,000 warrants. These proceeds plus the Company's estimated $2 million in w..
Research and Markets: Asia Pacific Markets for Dental Implants and Final Abutments - Valued at Just Over US$480 Million in 2008
DUBLIN -
Research and Markets (
|
|
|
|
|
|
|
|
|
